ARTICLE | Emerging Company Profile

VectorY: Forbion’s next-generation gene therapy play

Emerging Company Profile: With €31M, VectorY builds a toolbox to develop, manufacture vectorized antibodies

June 15, 2021 9:12 PM UTC

Forbion-backed VectorY is assembling a set of tools and key personnel to create vectorized antibody therapeutics designed to fill a gap in diseases where other mAbs and gene therapies have fallen short, beginning with ALS.

Rather than repairing broken or missing genes, VectorY Therapeutics hopes to become a next-generation gene therapy company capable of selectively changing the functionality of intercellular biochemistry, CEO Alexander Vos told BioCentury...

BCIQ Company Profiles